<b><i>Background:</i></b> Guidelines give robust recommendations on which biopsies should be taken when there is endoscopic suggestion of gastric inflammation. Adherence to these guidelines often seems arbitrary. This study aimed to give an overview on current practice in tertiary referral centres across Europe. <b><i>Methods:</i></b> Data were collected at 10 tertiary referral centres. Demographic data, the indication for each procedure, endoscopic findings, and the number and sampling site of biopsies were recorded. Findings were compared between centres, and factors influencing the decision to take biopsies were explored. <b><i>Results:</i></b> Biopsies were taken in 56.6% of 9,425 procedures, with significant variation between centres (<i>p</i> < 0.001). Gastric biopsies were taken in 43.8% of all procedures. Sampling location varied with the procedure indication (<i>p</i> < 0.001) without consistent pattern across the centres. Fewer biopsies were taken in centres which routinely applied the updated Sydney classification for gastritis assessment (46.0%), compared to centres where this was done only upon request (75.3%, <i>p</i> < 0.001). This was the same for centres stratifying patients according to the OLGA system (51.8 vs. 73.0%, <i>p</i> < 0.001). More biopsies were taken in centres following the MAPS guidelines on stomach surveillance (68.1 vs. 37.1%, <i>p</i> < 0.001). Biopsy sampling was more likely in younger patients in 8 centres (<i>p</i> < 0.05), but this was not true for the whole cohort (<i>p</i> = 0.537). The percentage of procedures with biopsies correlated directly with additional costs charged in case of biopsies (<i>r</i> = 0.709, <i>p</i> = 0.022). <b><i>Conclusion:</i></b> Adherence to guideline recommendations for biopsy sampling at gastroscopy was inconsistent across the participating centres. Our data suggest that centre-specific policies are applied instead.
Background and Aims: Many studies have shown a high effectiveness of fecal microbiota transplantation (FMT) in treatment of recurrent or refractory Clostridioides difficile infection (CDI). Nevertheless, data on long term outcomes and complications after FMT are still lacking. We aimed to evaluate the efficacy, the peri- procedural safety profile and the long-term efficacy and safety of FMT for recurrent CDI during a median follow up period of 24 months. Methods: Our study included 60 consecutive patients that were treated from 2015 to 2019 for recurrent CDI. In all patients FMT was performed through the nasoenteric tube placed during gastroscopy. Fresh donor feces were used for FMT from unrelated donors. Pre-FMT preparation included CDI treatment with oral vancomycin 500 mg q.i.d. for at least five days and proton pump inhibitor (PPI) administration before FMT. Follow up data included information about recurrent CDI episodes, early and late complications, health status at 3, 12 and 24 months after FMT. Results: FMT was performed for 60 patients (median age 72.5 years) with recurrent CDI. Clinical improvement after the first FMT procedure was observed in 48 patients (80%). Ten of 12 initially non-responding patients had a clinical resolution after a second FMT leading to an increased overall cure rate of 96.7 %. The remaining two patients needed a third FMT with a final overall cure rate of 100%. Nine of 60 patients were under immunosuppressive therapy. Six immunosuppressed patients were in the group of initial responders and the remaining three in the initially non-responder group. We observed a very low rate of adverse events in the short and long-term after FMT. During the first eight weeks after the FMT procedure, the death of three patients occurred, but they were not related to the FMT procedure. Patients were followed up for a median of 20 months, with the range from 12 to 55 months. During the follow-up period no long-term serious adverse events (SAE) were documented. Conclusions: Our study confirms excellent efficacy rates of FMT in the treatment of recurrent CDI. In addition, this study shows that it is possible to avoid short term SAE when FMT is administered via a nasoenteric tube by following a very stringent peri-procedural patient follow-up protocol. Our study also demonstrates good safety with a low rate of long-term adverse events after FMT.
Background Many studies have shown a high effectiveness of fecal microbiota transplantation (FMT) in treatment of recurrent or refractory Clostridioides difficile infection (CDI). Nevertheless, data on long term outcomes and complications after FMT are still lacking. We aimed to evaluate the efficacy, the peri- procedural safety profile and the long-term efficacy and safety of FMT for recurrent CDI during a median follow up period of 24 months. Methods Our study included 60 consecutive patients that were treated from 2015 to 2019 for recurrent CDI. In all patients FMT was performed through the nasoenteric tube placed during upper GI endoscopy. Fresh donor feces were used for FMT from unrelated donors. Pre-FMT preparation included CDI treatment with oral vancomycin 500 mg q.i.d. for at least five days and proton pump inhibitor (PPI) administration before FMT. Follow up data included information about recurrent CDI episodes, early and late complications, health status at 3, 12 and 24 months after FMT. Results FMT was performed for 60 patients (median age 72.5 years) with recurrent CDI. Clinical improvement after the first FMT procedure was observed in 48 patients (80%). Ten of 12 initially non-responding patients had a clinical resolution after a second FMT leading to an increased overall cure rate of 96.7 %. The remaining two patients needed a third FMT with a final overall cure rate of 100%. Nine of 60 patients were under immunosuppressive therapy. Six immunosuppressed patients were in the group of initial responders and the remaining three in the initially non-responder group. We observed a very low rate of adverse events in the short and long-term after FMT. During the first eight weeks after the FMT procedure, the death of three patients occurred, but they were not related to the FMT procedure. Patients were followed up for a median of 20 months, with the range from 12 to 55 months. During the follow-up period no long-term serious adverse events (SAE) were documented. Conclusion Our study confirms excellent efficacy rates of FMT in the treatment of recurrent CDI. In addition, this study shows that it is possible to avoid short term SAE when FMT is administered via a nasoenteric tube by following a very stringent peri-procedural patient follow-up protocol. Our study also demonstrates good safety with a low rate of long-term adverse events after FMT.
Raktažodžiai: pooperacinis skausmas, nesteroidiniai vaistai nuo uždegimo, intraveninis lornoksikamas, intraveninis acetaminofenas. SantraukaNesteroidiniai vaistai nuo uždegimo yra skirti įvai-raus tipo ir lokalizacijos skausmui malšinti. Gera pooperacinio skausmo kontrolė yra svarbi norint iš-vengti skausmo potencijuojamo paciento būklės pablogėjimo, pvz., tachikardijos, hipertenzijos, miokardo išemijos, alveolių ventiliacijos sumažėjimo, prasto žaizdų gijimo. Šiame tyrime lyginsime acetaminofeno ir lornoksikamo efektyvumą pooperaciniam skausmui malšinti. Darbo tikslas: įvertinti lornoksikamo analgezijos efektyvumo jėgą pooperaciniu laikotarpiu pacientams po radikalių prostatektomijų. Metodai. Įtraukti 35 pacientai, gydyti 2015-2016 metais LSMUL KK Urologijos skyriuje, kuriems atlikta radikali prostatektomija. Gavus raštišką sutikimą, atsitiktiniu būdu pacientams operacijos pabaigoje sušvirkščiami intraveninio lornoksikamo 8 mg arba acetaminofeno 1000mg. Pilvo skausmas vertinamas prieš operaciją, po operacijos praėjus 3, 6, 12 ir 24 valandoms. Rezultatai. Prieš operaciją pilvo skausmą lornoksikamo (L) grupėje jautė 1 (6,25 proc.) pacientas, o acetaminofeno (A) grupėje 1 (5,26 proc.) pacientas jautė rankos skausmą. Po operacijos praėjus 3 valandoms A grupėje 9 (47,37 proc.) pacientai skundėsi vidutinio stiprumo skausmu ir 3 (15,79 proc.) -stipriu skausmu. L grupėje po operacijos praėjus 3 valandoms 3 (18,75 proc.) pacientai jautė stiprų skausmą. Tarp A ir L vaistų po operacijos praėjus 3, 6, 12 ir 24 val. statistiškai reikšmingo skirtumo nebuvo (p=0,329; p=0,917; p=0,4; p=0,903, atitinkamai).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.